Dr. Neil Bander, Chairman
Dr. Neil H. Bander, MD is a physician-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan-Kettering Cancer Center.
Since joining the faculty of Cornell University Medical College (now Weill-Cornell Medical College) and New York-Presbyterian Hospital, he has directed both a laboratory effort and translational clinical research program to discover and clinically develop monoclonal antibodies for targeted cancer imaging and therapy.
team has the world's largest experience in antibody discovery and clinical development in urological cancers.
group developed the first series of monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could target and bind viable prostate cancer cells.
In part as a result of Dr. Bander's
efforts, PSMA has become recognized as the most prostate-cancer specific cell surface antigen known.
team and collaborators have developed PET imaging agents as well as radiolabeled- and drug-conjugated antibodies that have entered phase 1 and 2 clinical trials now extending to a dozen leading academic medical centers in the
US. The lead radiolabeled antibody is slated for international phase 3 trials in the coming months.
has long-standing interests and activities in the antibody-drug conjugate field.
Via joint efforts with multiple industry collaborators, Dr. Bander
has direct experience with virtually every major drug-linker platform available.
lectures and writes frequently on the topic.
In addition to collaborates with multiple academic groups, Dr. Bander also serves as a consultant and Advisory Board member to several bio-pharmaceutical companies.
He is a Joint Steering Committee member of the Pfizer-Weill/Cornell Center for Technological Innovation.
Antibodies developed in his
lab have been licensed to multiple bio-pharma companies for further development and commercialization.
Dr. Bander has authored approximately 175 peer-reviewed publications, and he is an inventor on approximately 100 US and foreign issued and pending patents.
He has received several honors including the FC Valentine Fellowship from the NY Academy of Med, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clarke Medal for Surgical Innovation from the Royal College of Surgeons (London).